Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon form of ALCL that was first reported in 1996. The U.S. Food and Drug Administration (FDA) first reported a possible link between women with breast implants and ALCL in 2011, based on its investigation of 34 published reports of ALCL.
BIA-ALCL typically develops in the fluid and the capsule around a textured surface breast implant with the most common...
Chimeric antigen receptor (CAR) T cells were approved by the Food and Drug Administration (FDA) to treat relapsed and refractory large B-cell...
A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...
MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, which begins Friday in Chicago.
The ASCO session brings together more than 32,000 oncology professionals from around the world to share the latest cancer treatment and oncology research results. Among highlighted findings from hundreds of...
Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...
Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...
Recently approved targeted and immunotherapy drugs are helping patients diagnosed with follicular lymphoma live longer. Knowing the available...
Tomas Sandoval was about to become a father for the second time in June 2014, when he was devastated to learn he had non-Hodgkin lymphoma...
Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping...
Two new clinical trials at MD Anderson are taking aim at mantle cell lymphoma – a rare form of non-Hodgkin’s lymphoma.
Most mantle...